What is Calidi Biotherapeutics's market cap?

Calidi Biotherapeutics (CLDI) has a market capitalization of $2.1M and trades on AMEX.

Who are Calidi Biotherapeutics's competitors?

Calidi Biotherapeutics's key competitors include Candel Therapeutics, Inc., Replimune Group, Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.

Who does Calidi Biotherapeutics partner with?

Calidi Biotherapeutics's notable partners include City of Hope, Northwestern University, University of Chicago, and others.

What subsidiaries does Calidi Biotherapeutics have?

Calidi Biotherapeutics's subsidiaries include StemVac GmbH.

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in United States of America and employs approximately 41 people. It has been publicly traded since 2023.

Calidi Biotherapeutics

CLDI

Calidi Biotherapeutics is a clinical-stage biotechnology company developing targeted oncolytic virus therapies designed to deliver genetic medicines to metastatic tumor sites.

Market cap

$2.11M-89.5%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

EPS-$0.43

Read the full report

Next report

Aug 18, 2026 (In 2 weeks)

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Amgen$203.07B+25.3%

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

CG Oncology$6.5B+229%

Candel Therapeutics, Inc.$729.8M+112%

Replimune Group$724.4M+194%

Calidi Biotherapeutics$2.1M-88.9%

By revenue growth

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Amgen20.96%+3.6pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

CG Oncology-3,682.61%+12,263pp

Candel Therapeutics, Inc.-15,156.45%—

Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company developing targeted oncolytic virus therapies designed to deliver genetic medicines to metastatic tumor sites. The company utilizes proprietary delivery platforms to shield viral payloads from immune system clearance, enabling systemic administration for the treatment of solid tumors. Its core value proposition lies in overcoming the historical limitations of local-only virotherapy by facilitating efficient dissemination to distal disease sites.

Competitive position

Calidi is an early-stage innovator in the oncolytic virus space, distinguished by its focus on systemic delivery and immune-evasion technologies.

GeographiesUnited States, Australia, Germany

Customer segmentsHealthcare providers, Pharmaceutical companies, Clinical trial participants

Business modelR&D intensive, IP licensing, Biopharmaceutical development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Specialized cell bank providers, Raw material suppliers for GMP manufacturing

CustomersClinical trial sites, Hospitals and oncology centers, Biotechnology licensing partners

CountryUnited States of America

Listed2023

Employees41.0

CEOEric E. Poma

SectorHealthcare

IndustryBiotechnology

Websitecalidibio.com

FilingsSEC EDGAR

Questions, answered.

What is Calidi Biotherapeutics's market cap?: Calidi Biotherapeutics (CLDI) has a market capitalization of $2.1M and trades on AMEX.
Who are Calidi Biotherapeutics's competitors?: Calidi Biotherapeutics's key competitors include Candel Therapeutics, Inc., Replimune Group, Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.
Who does Calidi Biotherapeutics partner with?: Calidi Biotherapeutics's notable partners include City of Hope, Northwestern University, University of Chicago, and others.
What subsidiaries does Calidi Biotherapeutics have?: Calidi Biotherapeutics's subsidiaries include StemVac GmbH.
Where is Calidi Biotherapeutics headquartered?: Calidi Biotherapeutics is headquartered in United States of America and employs approximately 41 people. It has been publicly traded since 2023.